TOVX
Price:
$2.0203
Market Cap:
$4.59M
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops...[Read more]
Industry
Biotechnology
IPO Date
2006-12-18
Stock Exchange
NYSE
Ticker
TOVX
According to Theriva Biologics, Inc.’s latest financial reports and current stock price. The company's current ROE is -61.28%. This represents a change of 268.29% compared to the average of -16.64% of the last 4 quarters.
The mean historical ROE of Theriva Biologics, Inc. over the last ten years is -55.26%. The current -61.28% ROE has changed 10.90% with respect to the historical average. Over the past ten years (40 quarters), TOVX's ROE was at its highest in in the March 2015 quarter at 760.49%. The ROE was at its lowest in in the June 2016 quarter at -247.69%.
Average
-55.26%
Median
-75.39%
Minimum
-708.84%
Maximum
1.01%
Discovering the peaks and valleys of Theriva Biologics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.14%
Maximum Annual ROE = 1.01%
Minimum Annual Increase = -243.09%
Minimum Annual ROE = -708.84%
Year | ROE | Change |
---|---|---|
2023 | -46.22% | 28.12% |
2022 | -36.08% | 66.48% |
2021 | -21.67% | -82.59% |
2020 | -124.51% | 19.08% |
2019 | -104.56% | 129.69% |
2018 | -45.52% | -104.49% |
2017 | 1.01% | -243.09% |
2016 | -708.84% | 160.14% |
2015 | -272.49% | 31.62% |
2014 | -207.03% | 156.00% |
The current ROE of Theriva Biologics, Inc. (TOVX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.66%
5-year avg
-66.61%
10-year avg
-55.26%
Theriva Biologics, Inc.’s ROE is greater than Lumos Pharma, Inc. (-157.99%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), less than Avalo Therapeutics, Inc. (178.36%), less than Catalyst Biosciences, Inc. (1.20%), less than Panbela Therapeutics, Inc. (545.45%), greater than Virpax Pharmaceuticals, Inc. (-1554.74%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Biodexa Pharmaceuticals Plc (-101.74%), greater than Praxis Precision Medicines, Inc. (-61.47%), greater than First Wave BioPharma, Inc. (-28.76%), greater than Salarius Pharmaceuticals, Inc. (-148.64%), greater than SAB Biotherapeutics, Inc. (-94.04%), less than Vaccinex, Inc. (1.11%), greater than GeoVax Labs, Inc. (-852.58%), greater than Kintara Therapeutics, Inc. (-454.05%), greater than Fresh Tracks Therapeutics, Inc. (-14.73%), greater than Lisata Therapeutics, Inc. (-46.22%), greater than Marker Therapeutics, Inc. (-78.91%), greater than Exicure, Inc. (-288.03%), greater than Protagenic Therapeutics, Inc. (-238.37%), greater than PMV Pharmaceuticals, Inc. (-21.96%),
Company | ROE | Market cap |
---|---|---|
-157.99% | $36.07M | |
-55460.19% | $8.98M | |
178.36% | $125.13M | |
1.20% | $19.42M | |
545.45% | $1.86M | |
-1554.74% | $3.37M | |
-243.91% | $3.19M | |
-101.74% | $3.30M | |
-61.47% | $1.25B | |
-28.76% | $5.99M | |
-148.64% | $2.10M | |
-94.04% | $38.39M | |
1.11% | $9.06M | |
-852.58% | $15.34M | |
-454.05% | $11.99M | |
-14.73% | $4.42M | |
-46.22% | $23.96M | |
-78.91% | $32.42M | |
-288.03% | $5.12M | |
-238.37% | $2.71M | |
-21.96% | $84.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theriva Biologics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Theriva Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Theriva Biologics, Inc.'s ROE?
How is the ROE calculated for Theriva Biologics, Inc. (TOVX)?
What is the highest ROE for Theriva Biologics, Inc. (TOVX)?
What is the 3-year average ROE for Theriva Biologics, Inc. (TOVX)?
What is the 5-year average ROE for Theriva Biologics, Inc. (TOVX)?
How does the current ROE for Theriva Biologics, Inc. (TOVX) compare to its historical average?